Here’s whether AstraZeneca PLC (AZN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bearish.
🔴
Bearish
Positives: strong 1-year return of +14.9%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.71% over 10 days); RSI 29 — oversold; 3-month momentum negative (-10.8%). Currently 20.4% off its 52-week high. Score: -5/7.
AZN is trading below its 200-day MA ($184.77) — a key warning sign the longer-term trend is under pressure. An RSI of 28.6 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +14.9% compares to +16.5% for SPY (trailed the market by 1.6%). The current 20.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $11,486 today
vs. S&P 500 (SPY) — same period trailed market by 1.6%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($184.77)
✗Above 50-day MA ($180.49)
!RSI(14) neutral zone (30–70) — currently 28.6
✓Positive return (+14.9%)
!Within 10% of period high (−20.4%)
Period Range $169.26
$142.98$212.71
RSI (14) 28.6
0 · OversoldOverbought · 100
Key Metrics
Price$169.26
Period Return+14.9%
Period High$212.71
Period Low$142.98
Drawdown−20.4%
MA-50$180.49
MA-200$184.77
RSI (14)28.6
Avg Volume (30d)2.4M
vs. SPYtrailed by 1.6%
Return Rank#411 of 999
Trend Signals
Price is below the 200-day moving average ($184.77)
Price is below the 50-day moving average ($180.49)